



**CSE: MDM      FSE: 2M0      OTCQB: MRPHF**

---

## **News Release**

**June 28, 2017 Kelowna, BC**

**Marapharm Ventures Inc. "Marapharm" announces a financial update on options and warrants**

**Marapharm announces that \$1,247,400.00 has been received from the closing of the June 17, 2017 warrant series.**

**One warrant series remains which will expire on September 6, 2017. Due to the early exercising of the September warrants Marapharm has received \$1,256,700.00 and \$3,498,800.00 remains to be exercised.**

**Marapharm has offered 9 warrant series to its shareholders. The total money received by Marapharm for the 9 series to date is \$12,153,200.00.**

**During the month of May 2017 Marapharm's Directors exercised 600,000 of their stock options for a total of \$300,000.00 received by Marapharm.**

**ABOUT MARAPHARM VENTURES INC.**

**[www.marapharm.com](http://www.marapharm.com)**

**Marapharm has more than 300,000 square feet of medical marijuana licenses for its land and facilities in WA, CA and NV. In Nevada, the building footprint is 360,000 square feet. The Nevada Department of Agriculture report by Tessa Rognier states that the average size of a**

cultivation facility in Nevada is 26,000 square feet. About three years ago, Marapharm applied in Canada to Health Canada for a MMPR (production and sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR. Marapharm owns 15 million shares and warrants of Veritas Pharma Inc., a public company.

Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website ([www.thecse.com](http://www.thecse.com)), the OTC website ([www.otcmarkets.com](http://www.otcmarkets.com)), and the SEDAR website ([www.sedar.com](http://www.sedar.com)) under the profile for Marapharm Ventures Inc.

#### **FOR FURTHER INFORMATION:**

[www.marapharm.com](http://www.marapharm.com) or Linda Sampson, CEO, 778-583-4476 email [info@marapharm.com](mailto:info@marapharm.com)

#### **STOCK EXCHANGES:**

*Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, in Europe, ticker symbol 2M0 on the FSE.*

Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.

#### **FORWARD - LOOKING STATEMENTS:**

**Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown**

risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.